Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Incyte < Previous 1 2 3 4 Next > Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer April 22, 2022 From Incyte Via Business Wire Tickers INCY Incyte to Report First Quarter Financial Results April 12, 2022 From Incyte Via Business Wire Tickers INCY Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo March 26, 2022 From Incyte Via Business Wire Tickers INCY Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease March 25, 2022 From Incyte Via Business Wire Tickers INCY Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting March 18, 2022 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conference February 15, 2022 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conference February 03, 2022 From Incyte Via Business Wire Tickers INCY Incyte Provides Update on Parsaclisib and MCLA-145 January 25, 2022 From Incyte Via Business Wire Tickers INCY Incyte to Report Fourth Quarter and Year-End 2021 Financial Results January 18, 2022 From Incyte Via Business Wire Tickers INCY Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura™) as a Treatment for Patients with Vitiligo December 14, 2021 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conferences December 14, 2021 From Incyte Via Business Wire Tickers INCY MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma December 11, 2021 From Incyte Via Business Wire Tickers INCY MOR Incyte Announces Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas December 11, 2021 From Incyte Via Business Wire Tickers INCY Incyte to Present at Upcoming Investor Conference November 09, 2021 From Incyte Via Business Wire Tickers INCY More than 35 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition November 04, 2021 From Incyte Via Business Wire Tickers INCY Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs November 02, 2021 From Incyte Via Business Wire Tickers INCY Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting November 01, 2021 From Incyte Via Business Wire Tickers INCY Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas November 01, 2021 From Incyte Via Business Wire Tickers INCY Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo October 28, 2021 From Incyte Via Business Wire Tickers INCY Incyte to Report Third Quarter Financial Results October 13, 2021 From Incyte Via Business Wire Tickers INCY Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo October 02, 2021 From Incyte Via Business Wire Tickers INCY Incyte Names New Member to Its Board of Directors September 28, 2021 From Incyte Via Business Wire Tickers INCY Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD) September 22, 2021 From Incyte Via Business Wire Tickers INCY Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD) September 21, 2021 From Incyte Via Business Wire Tickers INCY Incyte Announces Ruxolitinib Cream Data Accepted for Presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress September 13, 2021 From Incyte Via Business Wire Tickers INCY Incyte and MorphoSys Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma August 26, 2021 From Incyte Via Business Wire Tickers INCY MOR Incyte to Present at Upcoming Investor Conference August 17, 2021 From Incyte Via Business Wire Tickers INCY Incyte and InnoCare Announce Collaboration and License Agreement for Tafasitamab in Greater China August 16, 2021 From Incyte Via Business Wire Tickers INCY Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs August 03, 2021 From Incyte Via Business Wire Tickers INCY Incyte to Report Second Quarter Financial Results July 15, 2021 From Incyte Via Business Wire Tickers INCY < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.